Compromised glycolysis contributes to foot process fusion of podocytes in diabetic kidney disease: Role of ornithine catabolism
- PMID: 35780908
- DOI: 10.1016/j.metabol.2022.155245
Compromised glycolysis contributes to foot process fusion of podocytes in diabetic kidney disease: Role of ornithine catabolism
Abstract
Introduction: Compromised glycolysis in podocytes contributes to the initiation of diabetic kidney disease (DKD). Podocyte injury is characterized by cytoskeletal remodeling and foot process fusion. Compromised glycolysis in diabetes likely leads to switch of energy supply in podocyte. However, the underlying mechanism by which disturbed energy supply in podocytes affects the cytoskeletal structure of podocytes remains unclear.
Methods: Metabolomic and transcriptomic analyses were performed on the glomeruli of db/db mice to examine the catabolism of glucose, fatty, and amino acids. Ornithine catabolism was targeted in db/db and podocyte-specific pyruvate kinase M2 knockout (PKM2-podoKO) mice. In vitro, expression of ornithine decarboxylase (ODC1) was modulated to investigate the effect of ornithine catabolism on mammalian target of rapamycin (mTOR) signaling and cytoskeletal remodeling in cultured podocytes.
Results: Multi-omic analyses of the glomeruli revealed that ornithine metabolism was enhanced in db/db mice compared with that in db/m mice under compromised glycolytic conditions. Additionally, ornithine catabolism was exaggerated in podocytes of diabetic PKM2-podoKO mice compared with that in diabetic PKM2flox/flox mice. In vivo, difluoromethylornithine (DFMO, inhibitor of ODC1) administration reduced urinary albumin excretion and alleviated podocyte foot process fusion in db/db mice. In vitro, 2-deoxy-d-glucose (2-DG) exposure induced mTOR signaling activation and cytoskeletal remodeling in podocytes, which was alleviated by ODC1-knockdown. Mechanistically, a small GTPase Ras homolog enriched in the brain (Rheb), a sensor of mTOR signaling, was activated by exposure to putrescine, a metabolic product of ornithine catabolism.
Conclusion: These findings demonstrate that compromised glycolysis in podocytes under diabetic conditions enhances ornithine catabolism. The metabolites of ornithine catabolism contribute to mTOR signaling activation via Rheb and cytoskeletal remodeling in podocytes in DKD.
Keywords: Cytoskeleton; Diabetic kidney disease; Ornithine catabolism; PKM2; Podocytes; mTOR.
Copyright © 2022 Elsevier Inc. All rights reserved.
Similar articles
-
PFKP Activation Ameliorates Foot Process Fusion in Podocytes in Diabetic Kidney Disease.Front Endocrinol (Lausanne). 2022 Jan 14;12:797025. doi: 10.3389/fendo.2021.797025. eCollection 2021. Front Endocrinol (Lausanne). 2022. PMID: 35095764 Free PMC article.
-
Qizhi Jiangtang capsule activates podocyte autophagy in diabetic kidney disease by inhibiting phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathways.J Tradit Chin Med. 2023 Aug;43(4):667-675. doi: 10.19852/j.cnki.jtcm.20230428.001. J Tradit Chin Med. 2023. PMID: 37454251 Free PMC article.
-
Sirt6 ameliorates high glucose-induced podocyte cytoskeleton remodeling via the PI3K/AKT signaling pathway.Ren Fail. 2024 Dec;46(2):2410396. doi: 10.1080/0886022X.2024.2410396. Epub 2024 Oct 8. Ren Fail. 2024. PMID: 39378103 Free PMC article.
-
Podocytes, signaling pathways, and vascular factors in diabetic kidney disease.Adv Chronic Kidney Dis. 2014 May;21(3):304-10. doi: 10.1053/j.ackd.2014.03.011. Adv Chronic Kidney Dis. 2014. PMID: 24780459 Free PMC article. Review.
-
Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors.Cells. 2022 Dec 3;11(23):3913. doi: 10.3390/cells11233913. Cells. 2022. PMID: 36497173 Free PMC article. Review.
Cited by
-
mTOR pathway: A key player in diabetic nephropathy progression and therapeutic targets.Genes Dis. 2024 Mar 8;12(2):101260. doi: 10.1016/j.gendis.2024.101260. eCollection 2025 Mar. Genes Dis. 2024. PMID: 39717716 Free PMC article. Review.
-
NLRP3-mediated pyroptosis in diabetic nephropathy.Front Pharmacol. 2022 Oct 11;13:998574. doi: 10.3389/fphar.2022.998574. eCollection 2022. Front Pharmacol. 2022. PMID: 36304156 Free PMC article. Review.
-
Active role of amino acid metabolism in early diagnosis and treatment of diabetic kidney disease.Front Nutr. 2023 Sep 14;10:1239838. doi: 10.3389/fnut.2023.1239838. eCollection 2023. Front Nutr. 2023. PMID: 37781128 Free PMC article. Review.
-
The PI3K-Akt-mTOR pathway mediates renal pericyte-myofibroblast transition by enhancing glycolysis through HKII.J Transl Med. 2023 May 13;21(1):323. doi: 10.1186/s12967-023-04167-7. J Transl Med. 2023. PMID: 37179292 Free PMC article.
-
CerS6 links ceramide metabolism to innate immune responses in diabetic kidney disease.Nat Commun. 2025 Feb 11;16(1):1528. doi: 10.1038/s41467-025-56891-x. Nat Commun. 2025. PMID: 39934147 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous